A Study of Complete Molecular Response for Chronic Myeloid Leukemia in Chronic Phase Patients, Treated With Dasatinib
The purpose of this study is to evaluate complete molecular response of Dasatinib in patients for Philadelphia chromosome-positive chronic myeloid leukemia
Chronic Myeloid Leukemia
DRUG: dasatinib
Rate of complete molecular response (CMR) after treatment with dasatinib, at 12 months
Dasatinib of dose intensity, at 12 months|Expansions rate of large granular lymphocyte, at 12 months|Progression free survival, at 12 months|Number of Participants with Adverse Events, at 12 months
The purpose of this study is to evaluate complete molecular response of Dasatinib in patients for Philadelphia chromosome-positive chronic myeloid leukemia